[A20-32] Abemaciclib (breast cancer; combination with fulvestrant) - Benefit assessment according to §35a Social Code Book V
Last updated 15.06.2020
Commission awarded on 16.03.2020 by the Federal Joint Committee (G-BA).
Patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer
Initial endocrine-based therapy in postmenopausal patients and therapy in pre- and perimenopausal patients who have received prior endocrine therapy: hint of lesser benefit; postmenopausal women who have received prior endocrine therapy: indication of minor added benefit.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A18-72||Abemaciclib in combination with an aromatase inhibitor (breast cancer) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A18-73||Abemaciclib in combination with fulvestrant (breast cancer) - Benefit assessment according to §35a Social Code Book V||Commission completed|